Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
March 27 2017 - 4:00PM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the
appointment of Erik Wiberg as Executive Vice President of Corporate
Development. Mr. Wiberg joins Coherus with more than 30 years
of experience, including more than 18 years in various business
development and corporate finance roles at biopharmaceutical
companies, and 13 years in healthcare investment banking and equity
research. In this position, Mr. Wiberg will be responsible
for product licensing, corporate strategy, as well as M&A.
“We are very gratified to have a corporate
development professional of Mr. Wiberg’s caliber choose to join the
Coherus team,” said Denny Lanfear, President and Chief Executive
Officer of Coherus. “2017 is a transformational year for Coherus,
as we prepare our first product approval. Erik’s proven track
record of execution within corporate development will be critical
to effectively achieving our business objectives.”
Mr. Wiberg has extensive experience in corporate
development, completing numerous out-licensing, in-licensing,
merger and acquisition, and financing transactions and research
& development collaborations that achieved corporate priorities
and created significant value for shareholders at ALZA Corporation,
Johnson & Johnson, Anacor Pharmaceuticals, Inc., and Catalyst
Biosciences, Inc. Erik was most recently Senior Vice
President, Strategy and Corporate Development at Anacor
Pharmaceuticals, Inc. a company acquired by Pfizer in 2016 for $5.2
billion. He has also held leadership positions in corporate
strategy, new product planning and portfolio management. Erik
earned his dual degree in business and engineering from University
of Pennsylvania, where he attended the Wharton School of Business
and earned his Bachelor of Science in Economics, dual major in
Finance and Accounting, and the School of Engineering and Applied
Science where he earned his Bachelor of Applied Science with a
major in Computer Science Engineering.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that
develops and commercializes high-quality therapeutics for major
regulated markets. Biosimilars are intended for use in place of
existing, branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production, sales & marketing and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products in four therapeutic areas, oncology,
immunology (anti-TNF), ophthalmology and multiple sclerosis. For
additional information, please visit www.coherus.com.
Forward-Looking Statements Except
for the historical information contained herein, the matters set
forth in this press release, including statements regarding
Coherus’ plans, expectations, goals, objectives, strategies,
product pipeline, clinical studies, product development, and the
potential benefits of its products under development are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including statements regarding our ability to effectively achieve
our business objectives. Such forward-looking statements involve
substantial risks and uncertainties that relate to future events
and the actual results could differ significantly from those
expressed or implied by the forward-looking statements. Coherus
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Coherus’ business in general, please refer to the
Company’s Annual Report on Form 10-K filed with the SEC on March
13, 2016 and its subsequent periodic reports filed with the
SEC.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024